Intravitreal bevacizumab in recurrent diabetic vitreous haemorrhage after vitrectomy.
Ruiz-Moreno
José M
JM
Montero
Javier A
JA
Lugo
Francisco
F
Amat
Pedro
P
Staicu
Corina
C
D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000276:immunology / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D048909:Diabetes Complications; D006801:Humans; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors* / Q000276:immunology; D014821:Vitrectomy; D014822:Vitreous Body / Q000187:drug effects; D014823:Vitreous Hemorrhage / Q000209:etiology* / Q000628:therapy*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab